Author:
Song Ping-Wei,Liu Ye-Hui,Wang Tao,Yu Lei,Liu Jing-Li
Abstract
Abstract
Objective
To construct a predictive model for pain in patients undergoing hepatic arterial chemoembolization (TACE) in interventional operating room.
Methods
Through literature review and expert interviews, a questionnaire was prepared for the assessment of pain factors in patients with hepatic arterial chemoembolization. A prospective cohort study was used to select 228 patients with hepatic arterial chemoembolization in a tertiary and first-class hospital. The data of the patients in the pain group and the non-pain group were compared, and a rapid screening prediction model was constructed by univariate analysis and logistic regression analysis, and its prediction effect was tested.
Results
Tumor size, liver cancer stage, and chemoembolization with drug-loaded microspheres and pirarubicin hydrochloride (THP) mixed with lipiodol were independent predictors of pain in patients after hepatic arterial chemoembolization. Finally, the pain prediction model after TACE was obtained. The results of Hosmer–Lemeshow test showed that the model fit was good (χ2 = 13.540, p = 0.095). The area under the receiver operating characteristic curve was 0.798, p < 0.001.
Conclusion
The rapid screening and prediction model of pain in patients undergoing hepatic arterial chemoembolization has certain efficacy, which is helpful for clinical screening of patients with high risk of pain, and can provide reference for predictive pain management decision-making.
Funder
Yantai Yuhuangding Hospital
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–80. https://doi.org/10.1002/hep.29086.
2. Strippoli J, Durand R, Schmittbuhl M, Voyer R, Rompré P, Nishio C, et al. Pain and quality of life in patients undergoing guided piezocorticision-assisted orthodontic treatment. J ClinOrthod. 2017;51(12):792–9.
3. Luo J, Shao GL, Zheng JP, Chen YT, Yao Z, Zeng H, et al. The regularity and influencing factors of abdominal pain after hepatic arterial chemoembolization for primary liver cancer. J Interv Radiol. 2017;26(7):613–7. https://doi.org/10.3969/j.issn.1008-794X.2017.07.009.
4. Chen SH, Ji RB, Shi XJ, Wang Z, Zhu D. Retrospective analysis of efficacy, safety, and prognostic factors in a cohort of Chinese hepatocellular carcinoma patients treated with drug-eluting bead transarterial chemoembolization. Braz J Med Biol Res. 2019;52(12):e8467. https://doi.org/10.1590/1414-431X20198467. eCollection 2019.
5. Lv N, Kong YN, Mu LW, Pan T, Xie QK, Zhao M. Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma: a prospective randomized trial. EurRadiol. 2016;26(10):3492–9. https://doi.org/10.1007/s00330-016-4207-8. Epub 2016 Jan 22.